

# WHAT'S OLD & NEW IN BREAST IMAGING 2011

Margaret D. Taha, MD  
Diagnostic Radiology  
Fellowship: Breast and Body Imaging  
Wm Beaumont Hospital Royal Oak, MI

Radiology Regional Center

American College of Radiology



# Screening Breast Imaging

- Mammography
- Ultrasound
- MRI
- Nuclear Imaging
- Investigational Modalities
  - Thermography

# Mammography

- Screening – Patient without symptoms, low risk
  - Proven to decrease both mortality and morbidity due to breast cancer
- Radiology 2011- Random Control Trial – Tabar et al
- Two County Trial in Sweden - 29 year follow up of 130,000 women 40 -74 y/o
  - 1/2 invited to screening mammogram over 7 years – 85% screened
  - 1/2 not asked to screen
  - 30% decrease in breast cancer deaths in screened group

# Screening Mammography Current Recommendations

- American Cancer Society
- American College of Obstetricians and Gynecologists – July 2011
  - Women at average risk (< 20%)
    - Annual screening starting at age 40
    - No upper age limit – unless life expectancy is less than 5 years or significant co-morbidities
- U.S. Preventive Services Task Force
  - 2009 – Not implemented due to controversy
    - Only Screening for ages 50 – 74 every other year

# USPSTF Guidelines


- **Not implemented** – put on hold
- The reasons USPSTF Mortality reduction was low (15%) for <50 years
  - They utilized flawed Canadian NBSS trial with poor mammography technique
  - Excluding NBSS trial increases mortality reduction to 26 -30%
- They also recommend screening based on risk factors
  - Although 80% of patients diagnosed with breast cancer have no high risk factors



# What's the problem with Mammography

# NORMAL DIGITAL MAMMOGRAMS

Fatty breast



CC view



Dense breast



MLO View

# Digital Mammography

- Tissue superimposition hides pathologies in 2D
- Tissue superimposition mimics pathologies in 2D




Lesion Superimposed in 2D

What's new in evaluating the  
dense breast ?


# One Solution is TOMOSYNTHESIS

Tomosynthesis is a three-dimensional mammographic examination that **can minimize the effects of structure overlap** within the breast



# Digital Breast Tomosynthesis

- Takes Digital Mammographic images (~25 over 13 sec) as the x-ray tube moves in a narrow arc
- Reconstructed images with multiple 1mm slices parallel to detector (MLO and CC)
- Helpful to identify masses hiding in dense tissue, decrease recall rate for densities that are due to superimposition of tissues (pseudo lesions)





# Breast tomosynthesis unit





Park J M et al. Radiographics 2007;27:S231-S240

RadioGraphics


# 2D Digital Mammogram vs Tomosynthesis








RMLO




2D

## 2D Mammogram



## Tomosynthesis



# Ultrasound

## ■ Whole Breast Screening

### – Automated

- Pros - Reproducible, “complete” coverage of the breast tissue, currently investigational

### – Hand held

- Cons – Operator (tech) dependent, difficult to document inclusion of the entire breast tissue in a reproducible manner

### – RRC does not offer Whole breast screening Ultrasound

# American Cancer Society Guidelines for Screening Breast MRI as Adjunct to Mammography

- Recommend annual MRI screening (based on consensus opinion)
  - >20% lifetime risk (BRCA 1<sup>st</sup> degree relative or self)
  - Radiation to chest between ages 10 and 30
  - Li-Fraumeni syndrome and first-degree relatives of people with the syndrome
  - Cowden and Bannayan-Riley-Ruvalcaba syndromes and first-degree relatives

# Insufficient evidence to recommend for or against MRI screening

- Lifetime risk of 15-20%, models defined primarily dependent on family history
- LCIS or ALH
- ADH
- Heterogeneously or extremely dense breasts on mammography
- Personal history of breast cancer, including DCIS

# Recommend Against MRI Screening (based on expert consensus opinion)

- Women with less than 15% lifetime risk
- Premenopausal patients need to be scanned during early phase of menstrual cycle, optimally days 5-10. Otherwise pathology may be covered by hormonally activated tissue enhancement.

# Nuclear Imaging- Molecular Breast Imaging



- Breast Specific Gamma Imaging
- Positron Emission Mammography
  - Both use the increased metabolic activity of cancerous/highly active cells to stand out from the background uptake.
- Cons
  - Not easily biopsied if there is no mammographic or sonographic correlate
  - Low metabolic cancers may remain occult

# Nuclear Imaging

## Breast Specific Gamma Imaging

- Uses Tc 99m nuclear medicine isotope injected IV with imaging in MLO and CC views with specialized breast Gamma camera
- Increased uptake in tissue with increased mitochondrial activity – seen in cancers
- Can also be seen in fibrocystic breast tissue, some benign masses
- Maybe helpful in patient's who cannot undergo breast MRI due to claustrophobia or kidney disease


**BSGI of 39-year-old woman with new palpable mass in right breast  
IDC**



Brem R F et al. Radiology 2008;247:651-657

Radiology

# Cancer hidden in breast tissue on mammogram, visualized on Molecular Breast Imaging (BSGI)




# Nuclear Imaging

## Positron Emission Mammography

- Uses  $^{18}\text{F}$ -FDG IV
- Specialized PET imaging of only the breast
- Increased use of glucose (labeled with radioactive  $^{18}\text{F}$ ) by cancers


## Small invasive breast carcinomas with FDG PEM



Rosen E L et al. Radiographics 2007;27:S215-S229

RadioGraphics

## Small invasive breast carcinomas with FDG PEM



Rosen E L et al. Radiographics 2007;27:S215-S229

RadioGraphics

# Investigational Imaging

- Thermography – Theory: Increased blood flow to malignancies will be visible as increased temperature on the surface of the breast
- June 2, 2011 - **FDA Safety Communication: Breast Cancer Screening - Thermography is Not an Alternative to Mammography**
  - No research supporting Web site claims that thermography can detect early breast cancers or characterize clinical or imaging findings.

# Screening vs Diagnostic

Patient or Referring Physician

1. Lump
2. Thickening
3. Nipple retraction/discharge
4. Skin changes
5. Axillary symptoms
6. History of breast cancer
7. Work-up from screening exam
8. 6-month f/u

NO

YES

**Screening**

Pain without other symptoms

**Diagnostic**

# Diagnostic Breast Imaging at RRC

- <28 years old and no high risk history
  - Start with Ultrasound for mass
  - Mammography as needed
    - Bilateral to compare amount and distribution of fibroglandular tissue
- $\geq$  28 years
  - Start with bilateral mammography
  - Ultrasound as needed

# What the Radiologist needs to Know

## ■ Lumps/Bumps/Thickening

- **Location** – Clock position and distance from the nipple
  - marked on Rx (many patients will not know at the time of imaging, was marked on breast but she took a shower and washed it off)
- **Size** – golf ball vs pea

## ■ Nipple Discharge

### – **Suspicious**

- Bloody/Clear
- Spontaneous
- Unilateral

### – Benign

- White- usually hormone related – Prolactinoma
- Bilateral

# Diagnostic Breast Imaging

## ■ INDICATIONS

- Lump
- Thickening
- Nipple retraction/discharge
- Skin changes
- Axillary symptoms
- History of breast cancer/ high risk (Atypia)
- Work-up from screening exam
- 6-month f/u
- Family history of early breast cancer – BRCA genes

# Diagnostic Mammography

- Why do I need extra mammographic images
  - True lesions vs Pseudolesion
  - Characterization
    - Masses
      - Benign vs Suspicious
    - Calcifications
      - Benign vs Indeterminate vs Suspicious
  - Extent of a suspicious mass or calcifications

# Mass, palpable, asymmetric density, architectural distortion

## ■ Identify location



- Need two orthogonal views to pinpoint location
- Especially important to direct ultrasound evaluation / biopsy

## ■ Characterize abnormality

- Density
- Borders
- Associated calcifications



# Benign Masses

- Calcified Fibroadenoma
- Intramammary Lymph Node
- Hamartoma
- Skin masses



# Malignant Masses

- Spiculated borders
- Irregular shape
- Associated suspicious calcifications
- Distortion in the absence of prior surgery
- Higher density than surrounding tissue





# Calcifications

- Why do we care
  - Some cancers will become apparent only as calcifications
    - Mostly Ductal Carcinoma in Situ (DCIS)
    - But some Invasive (Infiltrating) cancers will not have a visible mass only calcifications
- Typically Benign Calcifications (no further work up)
- Certain to be Malignant
- Indeterminate- 10-20% chance of malignancy


# Typically Benign Calcifications (no further work up)

- Vascular
- Rim calcified oil cysts
- Skin (dermal)
- Milk of Calcium
- Secretory
- Macrocalcifications
- Diffusely scattered and bilateral





# Certain to be Malignant Microcalcifications

- crushed stone appearance
- fine linear branching
- dot-dash linear
- Triangular distribution pointing to the nipple



# Certain to be Malignant Microcalcifications



# Diagnostic Ultrasound



- Evaluate Palpable
- Characterize mass
  - Shape
  - Shadowing
  - Echogenicity
- Elastography

# Diagnostic Ultrasound

- To assess a mammographically apparent mass
  - Cyst vs solid
  - To identify mass so ultrasound biopsy can be performed
- Evaluate a palpable
- Evaluate for an underlying mass when malignant appearing calcifications are present
  - allowing for easier biopsy and better chance of biopsying the invasive portion of the cancer
- Evaluate ducts for masses when clear or bloody nipple discharge is present
- Evaluate axillary lymph nodes

# Breast Ultrasound

## Malignant Benign



**HYPERECHOIC  
RIM**


**POSTERIOR  
SHADOW**



**CYST**


**EDGE ARTIFACT**

**POSTERIOR  
ENHANCEMENT**



Images courtesy of JK Harness, MD


## Simple Cyst



Da Costa D et al. Radiographics 2007;27:S65-S77

RadioGraphics


# Lipoma



Chen L et al. Radiographics 2006;26:993-1006

RadioGraphics


**Intraductal lesion** in a 42-year-old woman with recent onset of a spontaneous bloody discharge from the nipple



Da Costa D et al. Radiographics 2007;27:S65-S77

RadioGraphics


## Papilloma in a 71-year-old woman



Doshi D J et al. Radiographics 2007;27:S53-S64

RadioGraphics


**Invasive ductal carcinoma** in a 52-year-old man with a palpable mass



Chen L et al. Radiographics 2006;26:993-1006

**RadioGraphics**

**Bilateral invasive ductal carcinoma** with bilateral axillary lymph node metastases in a 48-year-old man with Klinefelter syndrome and a history of bilateral breast lumps for several months.




Chen L et al. Radiographics 2006;26:993-1006

RadioGraphics

# Ultrasound Elastography

- Evaluates solid masses to determine the ability of the tissue to deform and return to normal
- Color coded
  - Benign masses more easily deform and return to normal than malignant masses. Thus may be followed instead of biopsied.


# Fibroadenoma with elasticity score of 1 in 51-year-old



Itoh A et al. Radiology 2006;239:341-350

Radiology

# Scirrhous type invasive ductal carcinoma with elasticity score of 5 in 55-year-old woman



Itoh A et al. Radiology 2006;239:341-350

Radiology



# Diagnostic MRI

- Characterize abnormality on Mammography/Ultrasound
- Palpable Without Imaging correlate
  - May be denied by insurance
- Evaluate for extent of Newly diagnosed cancer prior to treatment
- Evaluate for response to Neoadjuvant chemotherapy
- Evaluate for recurrent breast cancer

# Same patient

■ Mammogram

■ MRI of the breast –  
additional cancer  
circled



# Breast Biopsy Facts

- More than 1.8 million biopsies performed each year
- 80% are benign
- The standard of care is percutaneous biopsy if possible

American Cancer Society 2007 - 2008 Cancer Facts & Figures

American Society of Breast Surgeons 2006 Official Statements

Millenium Research Group, Hologic 2006

# Intervention

- **Percutaneous Image guided biopsy**
  - Stereotactic
  - Sonographic
  - MRI
- **Surgical biopsy – of imaging abnormality**
  - Wire localization
  - Radioactive Seed localization
    - New method to mark the abnormality instead of using a wire



# Stereotactic Biopsy




# Ultrasound-Guided Biopsy




# MRI-Guided Biopsy





# MRI-Guided Biopsy



# MRI-Guided Biopsy



# Radioactive Seed Localization






- Up to 5 days prior to surgery.
- Guided by either mammogram or ultrasound, a radiologist places one 4.5×0.8 mm titanium radioactive seed which contains 0.1 to 0.24 mCi of iodine, into a lesion using an 18-gauge spinal needle.
- At surgery, the surgeon uses a gamma probe to locate the seed, and then excises both the lesion and the seed, which is disposed of later following nuclear regulatory guidelines.
- The incidence of positive margins was reduced from 24% to 10% in Mayo Clinical trial.
- Offered at RRC Broadway office in conjunction with trained Breast surgeons.

# Image Guided Treatment

## Sonographically Guided Cryotherapy

### ■ Cryotherapy of a fibroadenoma



# ACCESS

- LEE COUNTY:
  - PARTNERS FOR BREAST CANCER CARE
  - FROM OUR HEARTS (PINE ISLAND)
  - LEE WE CARE
- COLLIER COUNTY: BOSOM BUDDIES
- AMERICAN CANCER SOCIETY
- KOMEN FOUNDATION
- UNITED WAY
- TO NAME ONLY A FEW

# Mobile Mammography





**Radiology Regional Center**  
radiologyregional.com

*"Earning Your Trust...  
Yesterday, Today, and Tomorrow"*

*(239) 936-2316*

American College of Radiology

